exRNAdisease

Entry Detail

---



General Information

Database ID: exR0087724 RNA Name: hsa-miR-1294 RNA Type: miRNA Chromosome: chr5 Starnd: + Coordinate: Start Site(bp): 154347153 End Site(bp): 154347174 External Links: hsa-miR-1294

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand CYB5R3 chr22 42617840 42649392 - STK40 chr1 36339624 36385896 - EIF4A1 chr17 7572706 7579006 + TRAPPC10 chr21 44012309 44106552 + ABCA1 chr9 104781006 104928155 - POGK chr1 166839447 166856344 + FGFR1 chr8 38400215 38468834 - KMT2A chr11 118436490 118526832 + RAB8A chr19 16111889 16134234 + TEX261 chr2 70985942 70994873 - ANKRD49 chr11 94493979 94499578 + PGRMC1 chrX 119236245 119244466 + PTMS chr12 6765516 6770952 + CRY2 chr11 45847118 45883248 + PTP4A1 chr6 63521746 63583436 + APLP2 chr11 130068147 130144811 + CDKN1B chr12 12715058 12722369 + UBE2G2 chr21 44768580 44801826 - PDPR chr16 70113626 70162537 + AKT2 chr19 40230317 40285536 - RNF157 chr17 76142465 76240493 - ZHX3 chr20 41178448 41317672 - ARHGAP28 chr18 6729718 6915716 + PRRC2B chr9 131373636 131500197 + FYCO1 chr3 45917899 45995824 - ZNF512B chr20 63956704 63969930 - SMAD7 chr18 48919853 48952052 - PDE4DIP chr1 148808181 149048286 + TAGLN2 chr1 159918107 159925732 - NACC1 chr19 13116862 13141147 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000247 chr10 74474868 74475660 + hsa_circ_0000798 chr17 65941524 65944422 + hsa_circ_0000246 chr10 74468040 74475660 + hsa_circ_0001085 chr2 191765289 191789319 + hsa_circ_0000744 chr17 15968183 15971435 - hsa_circ_0000799 chr17 65941524 65972074 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC007161.3 chr7 7640752 8004053 + AC021078.1 chr5 149494314 149504670 - AC022150.4 chr19 52650437 52653284 - AL022311.1 chr22 37876148 37895563 + H19 chr11 1995176 2001470 - LINC00265 chr7 39733430 39793092 + NEAT1 chr11 65422774 65445540 + TUG1 chr22 30969245 30979395 + Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.